The Latest Cardiac and Vascular News
WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio. TriNav® Advance expands Tri
BOSTON–(BUSINESS WIRE)– #MedTech–a2z Radiology AI receives FDA clearance for 10 findings, expanding its abdomen-pelvis CT triage portfolio to 17 findings across two devices.
Winners of the 2026 ITEA Awards of Excellence
Winners of the 2026 ITEA Awards of Excellence
September 16, 2026 SYMPHONY receives ITEA’s highest excellence award for connected healthcare ecosystemsAI FORSchung is recognized for innovation in AI-powered fiber-optic sensing Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare. SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for connecting healthcare data, clinical workflows and AI-supported decision tools through open, interoperable ecosystems. AI FORSchung received the ITEA Award of Excellence for Innovation for developing AI-driven methods to compress and analyze large volumes of fiber-optic sensing data. The awards were presented at the ITEA PO Days 2026 in Istanbul, Turkey. Connecting data and AI around clinical workflowsSYMPHONY developed a reusable, vendor-neutral reference architecture and demonstrated connected healthcare ecosystems across four clinical areas: prostate cancer, aortic aneurysm, atrial fibrillation and multiple sclerosis with clinical partners including Leiden University Medical Center, Amsterdam University Medical Center and Karolinska University Hospital. Philips also developed technology within SYMPHONY to automatically segment and measure vascular structures in medical images, supporting the assessment and follow-up of aortic aneurysms. The resulting functionality has received FDA clearance and CE marking and is included in AV Vascular, a part of the Philips AV Cardiovascular Suite.“Healthcare AI creates the greatest value when it can work with the information and clinical workflows that care teams already depend on,” said Sanjay Gandhi, Head of Medical Affairs & Clinical Partnerships at Philips. “SYMPHONY shows what becomes possible when healthcare providers, researchers and technology companies build around open standards and clinical pathways rather than isolated applications.” This real-world implementation was demonstrated through many close collaborations including the one between Philips and Leiden University Medical Center (LUMC), where standards-based integration was the focus. “Together with Philips, the LUMC demonstrated in SYMPHONY how vendor-neutral, standards-based integration of clinical data, imaging and applications, including the AV Vascular Segmentation solution, can support real clinical workflows,” said Jouke Dijkstra, Associate Professor, Vascular and Molecular Imaging at LUMC. The project created a reusable foundation for deploying innovative digital health solutions, also tailored towards AI algorithm integration, across institutions and disease areas.” Making growing sensing datasets more manageableFiber Optic RealShape (FORS) technology is used to support medical device navigation during image-guided procedures, generating large volumes of position data that need to be stored and processed efficiently. Within AI FORSchung, researchers developed new methods to make these data volumes easier to manage, demonstrating that FORS position data could be compressed more than 20 times while maintaining performance within the evaluated datasets.“The challenge extends well beyond healthcare,” said Ahmet Ekin, Senior Designer at Philips. “Fiber-optic sensing is also used to monitor critical infrastructure such as pipelines, bridges and tunnels, where continuous monitoring generates substantial volumes of data. By developing approaches that can be applied across healthcare, utilities and civil infrastructure, AI FORSchung demonstrated how advances in one field can help address shared data challenges in another.Both projects were conducted within ITEA, the Eureka Research, Development and Innovation Cluster on software innovation, funded by multiple national authorities including the Netherlands Enterprise Agency (RVO). Additional information about SYMPHONY can be found here: https://itea4.org/project/symphony.html; https://symphony-iteaproject.eu/Additional information about AI FORSchung can be found here: https://itea4.org/project/ai-forschung.html For further information, please contact: Joost MalthaPhilips Global External RelationsTel.: +31 6 1055816E-mail: joost.maltha@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
Winners of the 2026 ITEA Awards of Excellence
WAUKESHA, Wis., Sept. 15, 2026 /PRNewswire/ — A nationwide shortage of medical imaging professionals has prompted DeVry University and the Pulse Radiology Institute, an Edcetera company, to partner on a new MRI Technology Associate degree specialization. The hybrid program will combine…
Company to Showcase Expanded Digirad® Cardiac SPECT Portfolio, PET/CT Solutions, Windows 11 Modernization and Nationwide Imaging Service PITTSBURGH, Sept. 14, 2026 (GLOBE NEWSWIRE) — Catalyst MedTech today announced it will showcase its expanded nuclear cardiology portfolio at the 31st Annual Scientific Session & Exhibition of the American Society of Nuclear Cardiology (ASNC 2026), September 16–19, 2026, at Caesars Palace in Las Vegas. At Booth #121, Catalyst will feature Digirad® cardiac SPECT systems, PET/CT solutions, Windows 11 modernization, nationwide multi-vendor service, and cardiac imaging lifecycle support. Guided by the conference theme, “Be Part of What’s Next in Nuclear Cardiology,” the meeting will bring together the world’s leading cardiovascular imaging professionals to explore the latest advances in cardiac PET, SPECT, artificial intelligence, molecular imaging, and next-generation technologies. At Booth #121, Catalyst MedTech will demonstrate how providers can prepare for what’s next through an integrated approach that extends beyond imaging equipment—bringing together OEM innovation, modernization, nationwide service, clinical expertise, and lifecycle support to help healthcare organizations strengthen and grow their cardiac imaging programs. “The future of nuclear cardiology isn’t defined by a single technology—it’s defined by access, modernization, and the ability to continually evolve,” said Martin Shirley, President and CEO of Catalyst MedTech. “At Catalyst, we’re helping providers prepare for what’s next by combining OEM innovation, nationwide service, clinical expertise, and long-term lifecycle support in a way that few organizations can. Our goal is to give providers more options and greater flexibility to build the imaging programs their patients will need next.” See What’s Next at Booth #121 Visitors will have the opportunity to explore Catalyst MedTech’s expanding Digirad® OEM portfolio while learning how the company helps providers modernize existing imaging programs, maximize equipment performance, and plan for long-term growth. At ASNC 2026, Catalyst will highlight: CorCam™ dedicated cardiac SPECT system (formerly CardioMD®), now part of the expanded Digirad® OEM portfolioCardius® Series dedicated cardiac SPECT systemsX-ACT+® cardiac SPECT system with attenuation correction Windows 11 modernization for eligible legacy cardiac SPECT systemsISO-refurbished PET & PET/CT systemsNationwide OEM and multi-vendor service for cardiac SPECT, PET and PET/CT systemsImaging lifecycle management and modernization Cardiac PET program planning and implementation support Catalyst MedTech provides cardiac imaging solutions across SPECT and PET/CT, including new and refurbished imaging systems, equipment modernization, nationwide multi-vendor service, and clinical and program support. Beyond technology demonstrations, attendees will learn how Catalyst MedTech serves as a long-term partner by helping providers evaluate imaging strategies, modernize aging systems, improve operational performance, and support clinical growth through every stage of the imaging lifecycle. Meaningful Conversations About the Future of Cardiac Imaging As an ASNC 2026 Industry Collaboration Sponsor, Catalyst MedTech will participate in interactive small-group discussions with imaging leaders responsible for cardiac imaging strategy, modernization, and program development. Discussion topics will include: Replacing and modernizing aging cardiac SPECT systemsModernizing legacy cardiac SPECT systems to Windows 11Evaluating cardiac PET and PET/CT alongside existing SPECT programsProtecting imaging investments through lifecycle planningLeveraging nationwide OEM-trained, multi-vendor service support Whether organizations are replacing aging equipment, evaluating cardiac PET or PET/CT, modernizing existing technology, or seeking a trusted long-term imaging partner, Catalyst MedTech is helping providers navigate what’s next with more options, greater flexibility, and expertise across the imaging lifecycle. Attendees are invited to visit Catalyst MedTech at Booth #121 to experience the expanded Digirad® cardiac imaging portfolio, meet the team, and See What’s Next in Nuclear Cardiology. To learn more or schedule a meeting, visit: https://catalystmedtech.com/asnc-2026/https://catalystmedtech.com/asnc-2026-meeting/ About Catalyst MedTechCatalyst MedTech is a leading provider of nuclear medicine and molecular imaging solutions, including SPECT, PET and PET/CT, delivering OEM imaging systems, multi-vendor service, modernization, clinical support, and lifecycle management to healthcare providers across the United States. Through its expanding Digirad® OEM portfolio and nationwide service organization, Catalyst helps providers strengthen imaging programs, improve operational performance, and expand access to advanced diagnostic imaging. Guided by its purpose to provide value and access to advanced diagnostic imaging and related therapies that positively change people’s lives, Catalyst MedTech helps customers see what’s possible. www.catalystmedtech.com Media Contact:Kate KinsellDirector of MarketingCatalyst MedTechkkinsell@catalystmedtech.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/528c342d-8661-4d26-8f03-f22fcf1ff69e
SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ — NEXTBIOMEDICAL, a medical device company specializing in innovative therapeutic solutions, participated in CIRSE 2026, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held in Copenhagen,…
Company Engaged with Interventional Radiology Community at Leading Global Congress in CopenhagenCOPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen. Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA) System to interventional radiologists and healthcare professionals from around the world, providing an opportunity to engage with the global medical community and demonstrate the Company’s technology and approach to minimally invasive ablation. Baird Medical’s MWA System is designed to deliver precise and controlled ablation and features temperature control technology, stable 2.45 GHz microwave energy delivery, and a range of specialized probes designed to support different clinical applications. “Participating in CIRSE is an important part of Baird Medical’s continued engagement with the global medical community and reflects the international reach we have built across our business,” said Haimei Wu, Chairwoman and Chief Executive Officer of Baird Medical. “As we continue to strengthen our presence in the U.S. and across global markets, conferences like CIRSE provide valuable opportunities to connect with physicians from around the world, share our technology and deepen the relationships that support the broader adoption of minimally invasive treatment solutions.” Baird Medical’s participation at CIRSE 2026 reflects the Company’s broader commitment to advancing minimally invasive treatment technologies and strengthening its engagement with physicians and healthcare institutions globally. As the Company continues to expand its presence internationally, most recently in Pakistan, Vietnam, and Argentina, Baird Medical remains focused on providing reliable, precise and versatile technologies designed to support physicians and improve treatment options for patients. About Baird Medical Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system. Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact: Lee RothBurns McClellan for Baird MedicalLroth@burnsmc.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7e99f8d1-7274-40cd-813c-fe0e717dc3ad
SAN FRANCISCO–(BUSINESS WIRE)–Epsilon Health (“Epsilon”), the AI-native radiology practice reinventing how radiology is delivered, today emerged from stealth with $27.6 million in funding led by AlleyCorp, with participation from Uncork Capital, Renegade Partners, SemperVirens, and Jack Altman, who invested while serving as Managing Partner at Alt Capital. Epsilon is tackling one of the most urgent crises in American healthcare.Medical imaging is a foundational pillar of the U.S. healthcare sy
LAKE FOREST, Calif.–(BUSINESS WIRE)–SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy
Philips eV14-2v transducer
Philips eV14-2v transvaginal transducer, designed to support a broad range of gynecology and early obstetrics exams.
Clinician holding Philips eV14-2v transducer
A clinician holds the Philips eV14-2v transvaginal transducer.
Patient consultation with Philips Alturion ultrasound
A clinician consults with a patient alongside the Philips Alturion ultrasound system and eV14-2v transducer during a women’s health appointment.
September 3, 2026 FDA 510(k) cleared and CE marked, the eV14-2v combines exceptional image quality and broad clinical capabilities in one lightweight transducer, helping streamline exams, support diagnostic confidence, and improve the patient experience Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. FDA 510(k) cleared and CE marked, the eV14-2v is designed to support a broad range of gynecology and early obstetrics exams by combining image quality and broad clinical capabilities in a single lightweight transducer. The new transducer will be showcased at the 36th International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) World Congress. Across obstetrics and gynecology, clinicians care for women with diverse clinical needs, from routine gynecologic exams to early pregnancy assessments and more complex cases. Achieving the desired balance of penetration and image resolution may require switching between transducers, which can interrupt workflow and extend exam times. The eV14-2v is designed to address these challenges by providing enhanced penetration, improved resolution, and a wider field of view in a lightweight, ergonomic design. The transducer delivers a 41.7% increase in penetration, a 10% increase in 2D resolution, a 15.8% improvement in field of view, and a 22% lighter design, supporting imaging across routine and complex gynecology and early obstetrics exams [1]. “Advancing women’s health is a priority for Philips ultrasound, and we are committed to developing innovations that make women’s healthcare more accessible and more comfortable for patients,” said Ajay Gannerkote, Ultrasound Business Leader at Philips. “At Philips, we’re focused on bringing together high-quality imaging, intelligent workflows and connected capabilities to simplify the ultrasound experience for clinicians and patients. The eV14-2v transducer reflects that approach, giving clinicians greater versatility in a single transducer and helping support high-quality care for women.” Built specifically for gynecology and obstetrics imaging, the eV14-2v leverages PureWave crystal technology, first introduced by Philips, and features a lightweight ergonomic design that supports user comfort during exams. This gives clinicians detailed visualization of anatomy relevant to evaluating infertility and pelvic pain associated with conditions such as endometriosis and fibroids. Philips technology, including 2D and color resolution, supports the detection of fetal abnormalities, with the ability to delineate the cardiac chambers in a fetus as early as 13 weeks when the heart is the size of a single corn kernel [2]. “Reducing transducer changes during exams has a meaningful impact, not just on efficiency, but on the patient experience as well,” said Dr. Michael S. Ruma, MD, MPH, Perinatal Associates of New Mexico. “With the eV14-2v, we’re able to complete more exams with a single transducer while maintaining excellent image quality, which helps streamline our workflow and improve patient comfort.” The eV14-2v transducer can be used with Philips Collaboration Live, supporting real-time remote consultation during ultrasound exams. Clinicians can view live imaging, provide guidance during exams, and consult with care teams without requiring patient travel. This approach can help expand access to specialty care in underserved communities while supporting more efficient care delivery. In addition to the eV14-2v transducer, attendees at ISUOG 2026 will have the opportunity to experience Philips’ latest women’s healthcare ultrasound innovations firsthand, including the newly launched Alturion ultrasound system, EPIQ Elite, Lumify, and Flash with Collaboration Live, and learn more about the company’s ongoing efforts to advance ultrasound solutions for women worldwide. For further information on the eV14-2v transducer, please visit: Philips – eV14-2v Transducer FUS0929 – Philips. [1] Compared to the 3D9-3v transducer[2] Video image on file For further information, please contact: Jayme Maniatis Philips Global External Relations Tel.: 617-894-8368 E-mail: jayme.maniatis@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
Philips eV14-2v transducer
Clinician holding Philips eV14-2v transducer
Patient consultation with Philips Alturion ultrasound
